Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ACS Pharmacol Transl Sci
2021 Jun 07;44:1379-1389. doi: 10.1021/acsptsci.1c00079.
Show Gene links
Show Anatomy links
Cyclic Peptides as T-Type Calcium Channel Blockers: Characterization and Molecular Mapping of the Binding Site.
Depuydt AS
,
Rihon J
,
Cheneval O
,
Vanmeert M
,
Schroeder CI
,
Craik DJ
,
Lescrinier E
,
Peigneur S
,
Tytgat J
.
???displayArticle.abstract???
T-type calcium (CaV3) channels play a crucial role in the generation and propagation of action potentials in excitable cells and are considered potential drug targets for the treatment of neurological and cardiovascular diseases. Given the limited pharmacological repertoire for these channels, there is a great need for novel potent and selective CaV3 channel inhibitors. In this study, we used Xenopus oocytes to heterologously express CaV3.1 channels and characterized the interaction with a small cyclic peptide, PnCS1. Using molecular modeling, PnCS1 was docked into the cryo-electron microscopy structure of the human CaV3.1 channel and molecular dynamics were performed on the resultant complex. The binding site of the peptide was mapped with the involvement of critical amino acids located in the pore region and fenestrations of the channel. More specifically, we found that PnCS1 reclines in the central cavity of the pore domain of the CaV3.1 channel and resides stably between the selectivity filter and the intracellular gate, blocking the conduction pathway of the channel. Using Multiple Attribute Positional Scanning approaches, we developed a series of PnCS1 analogues. These analogues had a reduced level of inhibition, confirming the importance of specific residues and corroborating our modeling. In summary, functional studies of PnCS1 on the CaV3.1 channel combined with molecular dynamics results provide the basis for understanding the molecular interactions of PnCS1 with CaV3.1 and are fundamental to structure-based drug discovery for treating CaV3 channelopathies.
Arikkath,
Auxiliary subunits: essential components of the voltage-gated calcium channel complex.
2003, Pubmed
Arikkath,
Auxiliary subunits: essential components of the voltage-gated calcium channel complex.
2003,
Pubmed
Belardetti,
Linking calcium-channel isoforms to potential therapies.
2008,
Pubmed
Bladen,
Block of T-type calcium channels by protoxins I and II.
2014,
Pubmed
Bourinet,
Block of voltage-gated calcium channels by peptide toxins.
2017,
Pubmed
Burley,
Protein Data Bank (PDB): The Single Global Macromolecular Structure Archive.
2017,
Pubmed
Case,
The Amber biomolecular simulation programs.
2005,
Pubmed
Catterall,
Voltage-gated calcium channels.
2011,
Pubmed
Catterall,
International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels.
2005,
Pubmed
Catterall,
The conformational cycle of a prototypical voltage-gated sodium channel.
2020,
Pubmed
Chuang,
Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin.
1998,
Pubmed
,
Xenbase
Cribbs,
T-type calcium channel expression and function in the diseased heart.
2010,
Pubmed
Davidchack,
Langevin thermostat for rigid body dynamics.
2009,
Pubmed
Dolphin,
Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology.
2016,
Pubmed
Ellinor,
Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin.
1994,
Pubmed
,
Xenbase
Gamal El-Din,
Fenestrations control resting-state block of a voltage-gated sodium channel.
2018,
Pubmed
Gomora,
Block of cloned human T-type calcium channels by succinimide antiepileptic drugs.
2001,
Pubmed
Hille,
Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction.
1977,
Pubmed
Kalina,
New Insights into the Type II Toxins from the Sea Anemone Heteractis crispa.
2020,
Pubmed
Kozakov,
The ClusPro web server for protein-protein docking.
2017,
Pubmed
Mehrke,
The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels.
1994,
Pubmed
Miller,
MMPBSA.py: An Efficient Program for End-State Free Energy Calculations.
2012,
Pubmed
Olamendi-Portugal,
Two new scorpion toxins that target voltage-gated Ca2+ and Na+ channels.
2002,
Pubmed
,
Xenbase
Peigneur,
Where cone snails and spiders meet: design of small cyclic sodium-channel inhibitors.
2019,
Pubmed
,
Xenbase
Peigneur,
Small cyclic sodium channel inhibitors.
2021,
Pubmed
,
Xenbase
Perez-Reyes,
Molecular physiology of low-voltage-activated t-type calcium channels.
2003,
Pubmed
Pettersen,
UCSF Chimera--a visualization system for exploratory research and analysis.
2004,
Pubmed
Ramírez,
Conotoxins as Tools to Understand the Physiological Function of Voltage-Gated Calcium (CaV) Channels.
2017,
Pubmed
Roe,
PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data.
2013,
Pubmed
Sait,
Cannabidiol interactions with voltage-gated sodium channels.
2020,
Pubmed
Salari,
Molecular Interactions between Tarantula Toxins and Low-Voltage-Activated Calcium Channels.
2016,
Pubmed
,
Xenbase
Santi,
Differential inhibition of T-type calcium channels by neuroleptics.
2002,
Pubmed
Smith,
Molecular interactions of the gating modifier toxin ProTx-II with NaV 1.5: implied existence of a novel toxin binding site coupled to activation.
2007,
Pubmed
Tang,
Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs.
2016,
Pubmed
Tytgat,
Differential effects of verapamil and flunarizine on cardiac L-type and T-type Ca channels.
1988,
Pubmed
Tytgat,
Flunarizine inhibits a high-threshold inactivating calcium channel (N-type) in isolated hippocampal neurons.
1991,
Pubmed
Tytgat,
Mechanism of L- and T-type Ca2+ channel blockade by flunarizine in ventricular myocytes of the guinea-pig.
1996,
Pubmed
Zamponi,
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.
2015,
Pubmed
Zhao,
Cryo-EM structures of apo and antagonist-bound human Cav3.1.
2019,
Pubmed
Zhao,
Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca2+ Channel.
2019,
Pubmed